Amgen slips after late-stage trial data for Sjögren's disease therapy
Amgen's shares declined in premarket trading after presenting full Phase 3 trial results for dazodalibep, its Sjögren's disease therapy. The trial met its primary endpoint, with 1,500 mg and 3,000 mg doses showing ESSDAI score reductions of 5.6 and 5.2 points, respectively, over 48 weeks. The 1,500 mg dose also improved patient-reported dryness, a key secondary endpoint.
How this was made
The 30-second read
Why it matters
The data, while meeting the primary endpoint, fell short of expectations for a breakthrough, prompting a pre‑market sell‑off.
Market read
First‑report of pivotal trial data drives immediate price movement and may influence analyst outlooks on Amgen's autoimmune pipeline.
What to watch
Long‑term market may focus on the drug's safety profile and potential regulatory pathway rather than short‑term efficacy numbers.
Background
Amgen announced detailed results from its Phase 3 OASIZ 301 trial of dazodalibep for Sjögren's disease, showing modest reductions in disease activity scores.
Ticker impact
Amgen shares fell in pre‑market trading after the company released detailed Phase 3 trial results for dazodalibep in Sjögren's disease.
downward pressure as investors price in limited clinical benefit
While the primary endpoint was met, the magnitude of ESSDAI reduction is modest and patient‑reported dryness improvement is limited, prompting caution among investors.
Market effects
Biotech sector may see heightened scrutiny of late‑stage trial data, especially for autoimmune indications.
U.S. biotech stocks could experience modest pullback in early trading.
Limited; impact confined to Amgen and peers tracking autoimmune drug pipelines.
Counterpoint
Investors may view the primary‑endpoint success as a foothold for future data, potentially supporting a rebound.
Key entities
- CompanyAmgen
U.S. biotech firm developing dazodalibep for Sjögren's disease.
